Hot sale Cetrorelix - Travoprost CAS 157283-68-6 Assay 96.0%~102.0% API High Purity – Ruifu

Commercial Production with High Purity and Stable Quality
Chemical Name: Travoprost
CAS: 157283-68-6
Appearance: Colorless or Yellowish Oil
Assay: 96.0%~102.0% (anhydrous and solvent free basis)
Travoprost is used to treat glaucoma and ocular hypertension,is a potent and selective FP prostaglandin receptor agonist. 

Package: Bottle, Barrel, 25kg/Barrel, or according to customer’s requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Travoprost is used to treat glaucoma and ocular hypertension,is a potent and selective FP prostaglandin receptor agonist. Travoprost (Fluprostenol isopropyl ester), an isopropyl ester prodrug, is a high affinity, selective FP prostaglandin full receptor agonist.

Travoprost has the ocular hypotensive efficacy and has the potential for glaucoma and ocular hypertension. Travoprost was launched in the US as Travatan, an ophthalmic solution (0.004%) administered topically for the treatment of elevated intraocular hypertension (lOP) through open-angle glaucoma, a common optic neuropathy and a leading cause of blindness. Travoprost is the isopropyl ester of (+)-fluprostenol, a new prostaglandin derivative belonging to the PGF2α, analog class. This compound can be prepared in 8 steps from a bicyclic lactone aldehyde by a Wittig alkylidenation followed, after 2 ketonic reductions, by a lactol opening to prostenoic acid while protecting and deprotecting appropriately. Travoprost is a full agonist of FP receptors with a greater affinity than PGF2α, (K1 = 52 nM). Pharmacologic studies in rabbits treated daily for a week demonstrated a significant increase of the microvascular optic nerve head blood flow without significant alterations in the systemic flow. In several placebo-controlled clinical studies with hundreds of patients suffering from open-angle glaucoma or ocular hypertension, travoprost (1 to 4 pm daily) dose-dependently reduced lOP (by about 30% at 4 pm); it was shown equal or superior to latanoprost, another prostaglandin analog (5 pm daily) or the adrenergic ~-blocker timolol (500 pm bid). In addition, travoprost was safe and well tolerated with a low incidence of conjunctival hyperaemia.